

# AnteoTech Ltd (ASX: ADO)

## *Driving Innovation in Advanced Battery Technologies and Life Sciences*



**AnteoTech Ltd (ASX:ADO)**

4/26 Brandl St, Eight Mile Plains, QLD 4113

Australia

+61 7 3219 0085

investors@anteotech.com

www.anteotech.com

AnteoTech supplies advanced material solutions to the advanced battery technologies and life sciences markets. We leverage our market-leading cross-linking and binding chemical platform technology to develop and commercialise material solutions that meet our global customers' needs. Our Advanced Battery Technology division applies unique engineering expertise to address the demand for high-performance, low-cost, and sustainable materials in the global battery market, through products such as our patented cross-linker AnteoX™ and next-generation lithium-ion battery (LiB) high silicon anode formulations, Ultranode™.

Our Life Sciences division supplies advanced activation materials through our AnteoBind™ product suite to leading diagnostic test developers, enabling faster, more reliable and accurate test results. Headquartered in Brisbane, Australia, AnteoTech is listed on the Australian Stock Exchange as ASX: ADO.

### Battery Materials

**We produce next-generation battery technologies using our proprietary and patented technology platform.**

The battery market is undergoing a major transformation in anode technology, driven by changes in component materials, performance improvements and advanced designs. Through the incorporation of more silicon (the production of higher silicon anodes) cheaper, smaller, lighter, safer and more sustainable batteries with higher energy densities are increasingly being incorporated in battery designs. AnteoTech's products, Anteo X™ and Ultranode™ technologies (light and high performance), are at the forefront of this shift.


Independent testing of Anteo X™ in silicon anodes has demonstrated over 20% increases in battery life, along with reduced degradation of lithium-ion batteries (LiBs) over time. Anteo X™ enables the production of thinner, lighter, and more robust anodes, while also lowering total production costs by supporting the shift to silicon and reducing dependence on graphite, the conventional material used to store lithium ions in LiB anodes. Anteo X™ is designed for easy integration into existing LiB anode manufacturing processes.

Anteo X™ and Ultranode™ have been supplied to and are currently being tested and validated by chemical and battery material suppliers, electric vehicle manufacturers and consumer electronics battery manufacturers worldwide.

The figure below illustrates the impact of Anteo X™ in preserving the structural integrity of an anode.


Without  
Anteo X™

With  
Anteo X™




### Life Sciences

**We supply breakthrough cross linking bioconjugation technologies that enhance diagnostic tools and support the rapid development of new tests and vaccines.**



without AnteoBind™



with AnteoBind™

AnteoBind™ improves point-of-care diagnostic technology by enabling greater sensitivity, more reliable test results, and lower overall production costs for active components compared to current industry standards. This technology is driving growth in the point-of-care testing market, which continues to expand in the post-COVID environment.

AnteoTech has focused on working with the Indian pharmaceutical market, where the Indian Government's Production Linked Incentive for pharmaceuticals has supported significant growth, including US\$1 billion in Foreign Direct Investment in 2024.

AnteoTech currently supplies the Serum Institute of India, the world's largest vaccine manufacturer. In 2024, AnteoTech entered into a five-year, US\$1.8M (minimum) Purchase Agreement for the supply of AnteoBind™. The Company is also engaged in negotiations with multiple Indian companies to support the advancement of their technologies.

### Australian Government Support (Matched Funding)

AnteoTech has secured A\$1.4M from the Queensland Critical Minerals and Battery Technology Fund and A\$3.99M by ARENA to advance the development and commercialisation of its silicon-dominant anode, Ultranode™. Both grants are provided on a milestone, matched funding basis, enabling AnteoTech to leverage additional future investment.

# Our Products




## Advanced Battery Technologies

Anteo X™, an innovative, performance-enhancing, additive chemistry technology, has been developed to support lower-cost, longer-life high-silicon anode production for use in lithium-ion batteries (LiBs). Anteo X™ is a water-based cross-linker that can:

- Create tightly cohering network structure within the anode
- Be added as a final small component during the anode fabrication/manufacturing process
- Offer broad binder compatibility and provide a low-cost alternative to complex binders or minimise the use of expensive binders
- Support higher energy density and longer-life LiBs
- Improve separator safety
- In relation to Anteo X™ production and scale, AnteoTech has ISO 9001 certified quality management and production management systems in place.

PFAS free AnteoX's™ has been independently validated in multiple anode chemistries targeting different end-use applications. It is suitable for incorporation in LiBs used in e-mobility, EVs, and consumer products such as phones, computers, wearable devices, power tools, drones and remote control applications.

Ultranode™ technologies – Light and High Performance are fully integrated anodes containing AnteoTech's cross-linker technology, supporting high silicon integration (up to 70% silicon content) in LiBs. In 2024, Mercedes Benz placed an initial Ultranode™ order, and ARENA offered a \$3.99M grant to support the scale-up development of Ultranode.™



## Life Sciences



AnteoTech's AnteoBind™ enhances diagnostic performance, delivering heightened accuracy in both point-of-care and in vitro settings. Markets are under development across the healthcare, veterinary and agricultural sectors. In-house studies have shown that AnteoTech's newest product, AnteoBind™ NXT, outperforms the industry's standard chemistry, EDC/NHS, delivering superior performance and significant cost savings for bioconjugation activities.

AnteoBind™ improves protein pairing processes, testing accuracy, reproducibility and reliability. Its adaptability across various substrates makes it a preferred solution for challenging biomolecules used in the in vitro diagnostics market.

In 2024, a five-year Purchase Agreement was signed with the Serum Institute of India for the supply of AnteoBind™. Sixty-five per cent (65%) of all children globally receive at least one vaccine manufactured by the Serum Institute of India, such as vaccines for mumps and tetanus.

## Get In Touch

AnteoTech invites investors, strategic partners, and industry stakeholders to explore opportunities for collaboration. For more information, please visit [www.anteotech.com](http://www.anteotech.com) or contact the Investor Relations team directly. (07) 3219 0085 or [investors@anteotech.com](mailto:investors@anteotech.com)

